Table 3.
Cox Proportional Hazard Model for OS in Patients Treated by Irinotecan-Based and Oxaliplatin-Based Regimens.
| Variable | Irinotecan-Based Regimens (N = 35) | Oxaliplatin-Based Regimens (N = 83) | ||||||||||
| Univariate Analysis | Multivariate Analysis | Univariate Analysis | Multivariate Analysis | |||||||||
| HR* | 95% CI | P | HR | 95% CI | P | HR | 95% CI | P | HR | 95% CI | P | |
| Age | .91 | .91 | .21 | .83 | ||||||||
| ≤50 | 1.00 | 1.00 | 1.00 | 1.00 | ||||||||
| >50 | 0.92 | 0.21–4.06 | 0.91 | 0.17–4.78 | 0.66 | 0.35–1.27 | 0.92 | 0.43–1.98 | ||||
| Sex | .47 | .43 | .04 | .01 | ||||||||
| Female | 1.00 | 1.00 | 1.00 | 1.00 | ||||||||
| Male | 1.44 | 0.53–3.87 | 1.6 | 0.49–5.19 | 0.56 | 0.32–0.98 | 0.42 | 0.22–0.78 | ||||
| KRAS | .69 | .71 | .94 | .90 | ||||||||
| Mutant | 1.00 | 1.00 | 1.00 | 1.00 | ||||||||
| Wild type | 0.82 | 0.32–2.15 | 0.83 | 0.3–2.26 | 0.98 | 0.56–1.70 | 1.04 | 0.56–1.94 | ||||
| Initial diagnosis as stage IV | .49 | .45 | .14 | .16 | ||||||||
| No | 1.00 | 1.00 | 1.00 | 1.00 | ||||||||
| Yes | 1.41 | 0.53–3.80 | 1.52 | 0.51–4.56 | 1.69 | 0.85–3.39 | 1.77 | 0.81–3.87 | ||||
| Tumor site | .66 | .87 | .45 | .40 | ||||||||
| Distal | 1.00 | 1.00 | 1.00 | 1.00 | ||||||||
| Proximal | 0.75 | 0.21–2.64 | 0.88 | 0.19–4.01 | 1.26 | 0.70–2.29 | 0.74 | 0.37–1.49 | ||||
| No. of metastatic sites | ||||||||||||
| 1 | 1.00 | 1.00 | 1.00 | 1.00 | ||||||||
| 2 | 0.89 | 0.31–2.60 | .83 | 0.70 | 0.22–2.26 | .55 | 2.02 | 1.13–3.6 | .02 | 2.03 | 1.12–3.69 | .02 |
| ≥3 | 2.00 | 0.53–7.60 | .31 | 1.98 | 0.48–8.14 | .34 | 9.82 | 3.4–28.38 | <.001 | 8.22 | 2.45–27.6 | .001 |
*
HR, hazard ratio.